Biote Announces Purchase of Shares by Directors and CEO
Board Confidence in Biote: Several members of Biote's Board of Directors and CEO Bret Christensen have purchased approximately 260,000 shares of the company's stock, reflecting their confidence in Biote's business strategy and leadership.
Biote's Mission and Market: Biote focuses on preventive healthcare through personalized hormone optimization and wellness solutions, training medical providers to address early aging indicators in an underserved market.
Trade with 70% Backtested Accuracy
Analyst Views on BTMD
About BTMD
About the author
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
